Studies validating performance of Pall prion reduction technology presented at AABB

October 17, 2005

East Hills, NY (October 17, 2005) - - Research studies demonstrating the effectiveness of prion filtration technology to safeguard the blood supply are being presented at the AABB Annual Meeting in Seattle, Washington today. Prion diseases, such as variant Creutzfeldt-Jakob Disease (vCJD), the human form of Bovine Spongiform Encephalopathy or "mad cow" disease, are of growing concern to blood services worldwide because of the potential for transmission through transfusion from asymptomatic donors. Pall Corporation (NYSE: PLL) is presenting research results further validating the performance of its Leukotrap® Affinity Prion Reduction Filter System, which was CE marked with a 99.9 percent prion removal efficiency in May 2005. It is the first technology that reduces infectious prions from red cells, the most widely transfused blood component.

A new study conducted by the American Red Cross and the Eastern Virginia Medical School, Norfolk Va.,, found that red blood cells filtered through the Leukotrap Affinity Prion Reduction Filter System retain their therapeutic value and quality after 42 days of storage. The samples tested showed mean values of 85.0 and 82.9 percent in vivo red cell recovery, exceeding the FDA required mean of 75 percent for stored red cells. Post-storage hemolysis (breakdown of red cell membrane) values were well below the FDA maximum limit. The researchers concluded that both in vivo and in vitro results of this study indicate that leukoreduced red cell products filtered through the Pall system demonstrated acceptable quality for transfusion.

Sam Coker, Ph.D., Principal Scientist of Pall Corporation, presented results of research testing the filter against sporadic CJD, the most common form of prion disease that affects humans. The study, conducted with the Departments of Neurology, Psychiatry and Pathology of the New York University School of Medicine, showed a 99.9 percent reduction of the prion.

"This study, a first with a true human form of prion disease, provides additional confirmation of the performance of our technology to remove all types of prions that can adversely affect people," said Dr. Coker. The sporadic CJD study is one of a series of studies underscoring the filter's capability in reducing all types of prions from blood, including scrapie (a prion disease affecting sheep) and mouse-adapted human vCJD.

Dr. Coker also presented the results of research on the performance characteristics of the Pall Leukotrap Affinity Prion Reduction Filter under a range of different blood processing conditions, which may vary by country and blood center. The results showed that the new filter was effective in removing infectious scrapie prions from different preparations of red cell concentrates at different temperatures. In addition to prion removal, the study also measured the level of leukocyte reduction (resulting in removal of about 5 logs) and the quality of red cells before and after filtration, showing that normal cell qualities were maintained.

Pall developed the Pall Leukotrap Prion Affinity Reduction Filter System to help blood authorities around the world stop the transmission of prions as part of the Company's mission to help safeguard the global blood supply. Its prion technology is currently under evaluation by the Irish Blood Transfusion Service and the English National Blood Service for integration into their respective practices as a blood safety measure to reduce the risk of vCJD prion transmission. Pall is continuing its prion research and development program to apply its technologies to meet the specific requirements of each nation throughout Europe, the epicenter of vCJD, followed by North America and Asia.
About Pall Corporation
Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, semiconductor, water purification, aerospace and broad industrial markets. Total revenues for fiscal 2005 were $1.9 billion. The Company headquarters is in East Hills, New York with extensive operations throughout the world. Visit Pall at

Editors Notes:
  • Photos and additional information can be found on
  • Visit Pall at AABB Booth #301, Washington State Convention & Trade Center, Seattle, Oct.15-18
  • The studies noted in the above press release are:

    Excellent In Vivo 42-Day Red Blood Cell Recovery and Low Hemolysis Using a New Filter Designed to Remove Prions, Oct. 18, 8:30 a.m.-10:00 a.m., Room 608.

    Pall Leukotrap Affinity Filter Removed Human Creutzfeldt-Jakob Disease Prions from Red Cell Concentrates. Oct. 18, 4:00-5:30 p.m., Rm 608.

    Performance Characteristics of Pall Leukotrap Affinity Prion Reduction Filter, Oct. 17-18, 12:00-1:00 p.m., Exhibit Hall F.

    Media Contact:
    Marcia Katz
    Pall Corporation
    Tel: (516) 801-9128

    Pall Corporation

    Related Prions Articles from Brightsurf:

    How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
    How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases

    Household bleach inactivates chronic wasting disease prions
    A 5-minute soak in a 40% solution of household bleach decontaminated stainless steel wires coated with chronic wasting disease (CWD) prions, according to a new study published in PLOS One.

    Mad cow disease: A computational model reveals the mechanism of replication of prions
    An article published in the journal PLOS Pathogens reports a realistic computational model for the structure and mechanism of replication of prions, infectious agents responsible for mad cow disease and other neurodegenerative disorders of human and animals.

    Breakthrough in chronic wasting disease research reveals distinct deer, elk prion strains
    Researchers have developed a new gene-targeted approach to study chronic wasting disease in mice, allowing opportunities for research that has not previously existed.

    How prions invade the brain
    The spread of prions to the brain does not occur by direct transmission across the blood-brain barrier, according to a study published Nov.

    Eyes of CJD patients show evidence of prions
    NIH scientists and colleagues have found evidence of the infectious agent of sporadic Creutzfeldt-Jakob disease (CJD) in the eyes of deceased CJD patients.

    Creutzfeldt-Jakob disease spreads prions throughout the eyes, researchers find
    Researchers recently studied the eyes of 11 people with sporadic Creutzfeldt-Jakob disease (sCJD), the most common and well-known prion disorder.

    CWD prions discovered in Wisconsin soils for the first time
    New research out of the University of Wisconsin-Madison has, for the first time, detected prions responsible for chronic wasting disease (CWD) in samples taken from sites where deer congregate.

    Researchers find infectious prions in Creutzfeldt-Jakob disease patient skin
    In a Science Translational Medicine study published today, Case Western Reserve University School of Medicine researchers found that CJD patients also harbor infectious prions in their skin, albeit at lower levels.

    Getting under the skin of prion disorders
    Infectious prion proteins -- the causative agents of the fatal neurodegenerative disorder Creutzfeldt-Jakob disease -- can be detected in the skin of afflicted individuals, researchers now report.

    Read More: Prions News and Prions Current Events
  • is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to